Literature DB >> 7756503

Bacteremia due to vancomycin-dependent Enterococcus faecium.

M Green1, J H Shlaes, K Barbadora, D M Shlaes.   

Abstract

A recipient of small-bowel and liver transplants developed recurrent fever and polymicrobial bacteremia due to multiply resistant Enterobacter cloacae and an inducible VanB strain of Enterococcus faecium while receiving therapy with amikacin, imipenem, and vancomycin. These organisms could not be subcultured onto blood agar but did grow around the vancomyin disk on a direct-susceptibility test plate. Additional testing confirmed the strain as E. faecium, which would not grow in the absence of vancomycin. Growth around a disk containing D-alanyl-D-alanine was demonstrated. Spontaneous vancomycin-independent revertants were obtained at a frequency of approximately 1 x 10(-6). Two classes of vancomycin-independent revertants were obtained: one that was constitutively vancomycin resistant and one that was nonconstitutively vancomycin resistant. We hypothesize that the normal D-ala ligase is not expressed in the vancomycin-dependent strain; thus survival of these strains is dependent on expression of the VanB ligase, which produces a depsipeptide precursor that is resistant to vancomycin binding. This is the second reported case involving a clinically important vancomycin-dependent enterococcal strain. Awareness of the existence of these strains is important, especially when clinical and microbiological data are consistent with infection due to a fastidious or nutritionally-deficient organism.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7756503     DOI: 10.1093/clinids/20.3.712

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  10 in total

Review 1.  Vancomycin-resistant enterococci.

Authors:  Y Cetinkaya; P Falk; C G Mayhall
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

2.  D-Ala:D-Ala ligase gene flanking the vanC cluster: evidence for presence of three ligase genes in vancomycin-resistant Enterococcus gallinarum BM4174.

Authors:  Ole-Herman Ambúr; Peter E Reynolds; Cesar A Arias
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

3.  Vancomycin-dependent Enterococcus faecalis clinical isolates and revertant mutants.

Authors:  F Van Bambeke; M Chauvel; P E Reynolds; H S Fraimow; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

Review 4.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

Review 5.  Infections in solid-organ transplant recipients.

Authors:  R Patel; C V Paya
Journal:  Clin Microbiol Rev       Date:  1997-01       Impact factor: 26.132

6.  Specificity of induction of glycopeptide resistance genes in Enterococcus faecalis.

Authors:  M Baptista; F Depardieu; P Courvalin; M Arthur
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

7.  Improved detection of vanB2-containing enterococcus faecium with vancomycin susceptibility by Etest using oxgall supplementation.

Authors:  E A Grabsch; K Chua; S Xie; J Byrne; S A Ballard; P B Ward; M L Grayson
Journal:  J Clin Microbiol       Date:  2008-04-23       Impact factor: 5.948

8.  Vancomycin-dependent Enterococcus faecium isolated from stool following oral vancomycin therapy.

Authors:  L L Dever; S M Smith; S Handwerger; R H Eng
Journal:  J Clin Microbiol       Date:  1995-10       Impact factor: 5.948

9.  Draft Genome Sequence of a Vancomycin-Resistant and Vancomycin-Dependent Enterococcus faecium Isolate.

Authors:  Marion Blaschitz; Sarah Lepuschitz; Laura Wagner; Franz Allerberger; Alexander Indra; Werner Ruppitsch; Steliana Huhulescu
Journal:  Genome Announc       Date:  2016-04-07

10.  Nosocomial infection with vancomycin-dependent enterococci.

Authors:  Paul A Tambyah; John A Marx; Dennis G Maki
Journal:  Emerg Infect Dis       Date:  2004-07       Impact factor: 6.883

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.